drug
temsirolimus
Marketedupdated 3mo agoby Accord Healthcare Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying temsirolimus
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- phase2A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
- phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- phase1A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
- N/ATorisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
- phase3Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
- —Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- —Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 10, 2032
~5.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Nov 10, 2032patentUS 8791097*PED
- May 10, 2032method-of-use (U-1550)US 8791097
- Jul 20, 2026patentUS 8026276*PED
- Jan 20, 2026formulationUS 8026276
News(0)
no news has mentioned this drug yet
Data sources
last refreshed just now
Found something off?
comments(0)
5-min edit window · permanent after that